Melanoma

Biomarkers Predict Resistance to Immunotherapies in Melanoma

Researchers found potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to cause progression of melanoma cells.

Melanoma

Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer

The blood test followed by PET-CT imaging was 99.6% specific for cancer.

Melanoma

New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics

The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.

Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels

Dec 20, 2018 | Melanoma, Prostate

The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.

Protagen and German National Center for Tumor Diseases, Heidelberg, to Investigate Immunocompetence of Cancer Patients

Dec 3, 2018 | Melanoma, Research

Protagen has extended its collaboration with the National Center for Tumor Diseases, Heidelberg, to investigate the immunocompetence of urothelial cancer patients receiving immunotherapy.

Immunotherapy Effective against Hereditary Melanoma

Nov 14, 2018 | Melanoma, Research

Almost two-thirds of the patients with CDKN2A mutations responded with tumors that shrank, and for a third of the patients the tumors disappeared completely.

Collaborators Aim to Improve Therapy Decisions in Immunooncology

Nov 7, 2018 | Melanoma

The partners will apply deep machine learning to develop biomarker models for relevant treatment-associated endpoints such as immune-related adverse events, clinical response, or survival.

Asuragen Expands Oncology Portfolio

Oct 15, 2018 | Lung Cancer, Melanoma, Software

The panel accurately and sensitively detects more than 1,600 variants of clinical significance.

Bio-Rad Launches Anti-Idiotypic Antibodies Targeting Pembrolizumab and Nivolumab

Jun 25, 2018 | Lung Cancer, Melanoma, Standards

Anti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.

Liquid Biopsy Scores Immunotherapy Effectiveness

Jun 19, 2018 | Culture Media, Lung Cancer, Melanoma, Molecular Diagnostics

Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.

Protagen, Gustave Roussy Partner on Risk Profiling of Cancer Patients

May 3, 2018 | Melanoma

Protagen and Gustave Roussy will partner to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events in cancer patients treated with checkpoint inhibitors.

Delivering on the Promise of NGS for Clinical Diagnostics

Mar 12, 2018 | Lung Cancer, Melanoma, Pancreatic, Software, Standards

Presenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.

Biodesix Test May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors

Jan 17, 2018 | Melanoma, Research

Study results have demonstrated that a test based on a protein signature associated with patient outcomes in metastatic melanoma can effectively predict survival among patients receiving programmed cell death-1 antibodies.

Skin Cancer Study Shows Promise for Diagnosing a Rare Type of Melanoma

Jun 6, 2017 | Melanoma, Research

Led by investigators at the Translational Genomics Research Institute, researchers have identified a protein target that opens a window into acral lentiginous melanoma and may aid in diagnosis.

Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy

Nov 24, 2015 | Melanoma, Research

Early data suggests the test’s clinical potential for guiding anti-PD-1 therapy.

Category: Melanoma

Melanoma

Melanoma

Melanoma